{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:48:41Z","timestamp":1775695721661,"version":"3.50.1"},"reference-count":136,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.pharmthera.2022.108180","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T11:12:13Z","timestamp":1648725133000},"page":"108180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Distinct mechanisms underlying therapeutic potentials of CD20 in neurological and neuromuscular disease"],"prefix":"10.1016","volume":"238","author":[{"given":"Tao-Xiang","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Teng","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bi-Wen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.pharmthera.2022.108180_bb0005","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/jnnp-2020-325302","article-title":"Autoimmune encephalitis: Proposed recommendations for symptomatic and long-term management","volume":"92","author":"Abboud","year":"2021","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0010","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/rheumatology\/kew396","article-title":"Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab","volume":"56","author":"Aggarwal","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0015","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1212\/WNL.0000000000004923","article-title":"Necrosis in anti-SRP(+) and anti-HMGCR(+)myopathies: Role of autoantibodies and complement","volume":"90","author":"Allenbach","year":"2018","journal-title":"NEUROLOGY"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0020","series-title":"Rituximab for the treatment of neuromyelitis optica spectrum disorder","author":"Banerjee","year":"2021"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0025","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/ana.21939","article-title":"Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?","volume":"67","author":"Bar-Or","year":"2010","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0030","doi-asserted-by":"crossref","first-page":"e1805","DOI":"10.1212\/WNL.0000000000005516","article-title":"Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study","volume":"90","author":"Bar-Or","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nri2454","article-title":"The who, how and where of antigen presentation to B cells","volume":"9","author":"Batista","year":"2009","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0040","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1182\/blood-2006-04-020057","article-title":"Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab","volume":"108","author":"Bowles","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0045","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1083\/jcb.121.5.1121","article-title":"Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes","volume":"121","author":"Bubien","year":"1993","journal-title":"The Journal of Cell Biology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0050","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00262-001-0247-1","article-title":"Binding to CD20 by anti-B1 antibody or F(ab\u2019)(2) is sufficient for induction of apoptosis in B-cell lines","volume":"51","author":"Cardarelli","year":"2002","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102428","article-title":"Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice","volume":"45","author":"Carnero Contentti","year":"2020","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0060","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1111\/ene.14498","article-title":"Ocrelizumab in a case of refractory chronic inflammatory demyelinating polyneuropathy with anti-rituximab antibodies","volume":"27","author":"Casertano","year":"2020","journal-title":"European Journal of Neurology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0065","first-page":"8","article-title":"Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders","volume":"93","author":"C\u00e9line Louapre","year":"2022","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0070","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/nan.12574","article-title":"Review: Recent advances in the understanding of the pathophysiology of neuromyelitis optica spectrum disorder","volume":"46","author":"Chang","year":"2020","journal-title":"Neuropathology and Applied Neurobiology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0075","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108180_bb0080","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00415-020-10362-z","article-title":"Rituximab for the treatment of multiple sclerosis: A review","volume":"269","author":"Chisari","year":"2022","journal-title":"Journal of Neurology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0085","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1365-2990.2010.01153.x","article-title":"Review: An update on inflammatory and autoimmune myopathies","volume":"37","author":"Dalakas","year":"2011","journal-title":"Neuropathology and Applied Neurobiology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0090","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMc1506827","article-title":"Inflammatory muscle diseases","volume":"373","author":"Dalakas","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0095","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in myasthenia gravis in the era of biologics","volume":"15","author":"Dalakas","year":"2019","journal-title":"Nature Reviews. Neurology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0100","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0105","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrneurol.2011.121","article-title":"Advances in the diagnosis, pathogenesis and treatment of CIDP","volume":"7","author":"Dalakas","year":"2011","journal-title":"Nature Reviews. Neurology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0110","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1212\/WNL.0000000000000570","article-title":"Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease","volume":"83","author":"Dale","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0115","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1152\/physrev.00010.2016","article-title":"Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system","volume":"97","author":"Dalmau","year":"2017","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0120","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJMra1708712","article-title":"Antibody-mediated encephalitis","volume":"378","author":"Dalmau","year":"2018","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0125","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1001\/jamaneurol.2014.488","article-title":"Abnormal neurons in teratomas in NMDAR encephalitis","volume":"71","author":"Day","year":"2014","journal-title":"JAMA Neurology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01943","article-title":"A tridimensional model for NK cell-mediated ADCC of follicular lymphoma","volume":"10","author":"Decaup","year":"2019","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0135","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1007\/s00415-020-10041-z","article-title":"Antibodies against the node of Ranvier: A real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera","volume":"267","author":"Delmont","year":"2020","journal-title":"Journal of Neurology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0140","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri3871","article-title":"Immunopathology of multiple sclerosis","volume":"15","author":"Dendrou","year":"2015","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0145","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000719","article-title":"Ocrelizumab initiation in patients with MS: A multicenter observational study","volume":"7","author":"Ellwardt","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0150","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/icb.2015.48","article-title":"The MS4A family: Counting past 1, 2 and 3","volume":"94","author":"Eon Kuek","year":"2016","journal-title":"Immunology and Cell Biology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0155","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/brain\/awy301","article-title":"Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis","volume":"142","author":"von Essen","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0160","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/rheumatology\/kew146","article-title":"Rituximab in the treatment of inflammatory myopathies: A review","volume":"56","author":"Fasano","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.725700","article-title":"Efficacy and safety of immunotherapies in refractory myasthenia gravis: A systematic review and meta-analysis","volume":"12","author":"Feng","year":"2021","journal-title":"Frontiers in Neurology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0170","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nature Reviews. Disease Primers"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci10100758","article-title":"Anti-CD20 agents for multiple sclerosis: Spotlight on ocrelizumab and ofatumumab","volume":"10","author":"Florou","year":"2020","journal-title":"Brain Sciences"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0180","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2077","article-title":"Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: What do we know after 20 years of rituximab","volume":"29","author":"Focosi","year":"2019","journal-title":"Reviews in Medical Virology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0185","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1177\/1352458520918375","article-title":"A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis","volume":"27","author":"Fox","year":"2021","journal-title":"Multiple Sclerosis"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0190","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/CCO.0000000000000107","article-title":"Obinutuzumab: A new class of anti-CD20 monoclonal antibody","volume":"26","author":"Gagez","year":"2014","journal-title":"Current Opinion in Oncology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0195","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s13311-017-0557-4","article-title":"Ocrelizumab and other CD20(+) B-cell-depleting therapies in multiple sclerosis","volume":"14","author":"Gelfand","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0200","first-page":"10","article-title":"Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I_II distinction of CD20 antibodies","volume":"118","author":"Gerhard Niederfellner","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0205","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0210","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis - autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nature Reviews. Neurology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0215","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nature Reviews. Disease Primers"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0220","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: Subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0225","article-title":"Targeting B cells to modify MS, NMOSD, and MOGAD: Part 1","volume":"8","author":"Graf","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0230","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1212\/CON.0000000000000738","article-title":"Monitoring, switching, and stopping multiple sclerosis disease-modifying therapies","volume":"25","author":"Gross","year":"2019","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0235","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0240","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus Teriflunomide in Multiple Sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0245","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0250","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0255","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","article-title":"Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models","volume":"12","author":"Herter","year":"2013","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0260","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1006\/bcmd.2000.0287","article-title":"Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis","volume":"26","author":"Hofmeister","year":"2000","journal-title":"Blood Cells, Molecules & Diseases"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108180_bb0265","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1007\/s00415-021-10646-y","article-title":"Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: A systematic review and meta-analysis","volume":"269","author":"Hu","year":"2022","journal-title":"Journal of Neurology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0270","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/cyto.990140212","article-title":"Cd20 (Pan-B cell) antigen is expressed at a low-level on a subpopulation of human lymphocytes-T","volume":"14","author":"Hultin","year":"1993","journal-title":"Cytometry"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0275","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/CND.0b013e3181ff49f3","article-title":"A review: The use of rituximab in neuromuscular diseases","volume":"12","author":"Ibrahim","year":"2010","journal-title":"Journal of Clinical Neuromuscular Disease"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0280","first-page":"5570566","article-title":"Rituximab treatment in acute disseminated encephalomyelitis associated with salmonella infection","volume":"2021","author":"Kacmaz","year":"2021","journal-title":"Case Rep Pediatr"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0285","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"Kappos","year":"2011","journal-title":"The Lancet"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0290","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.02069","article-title":"B cell activation involves nanoscale receptor reorganizations and inside-out signaling by Syk","volume":"3","author":"Kl\u00e4sener","year":"2014","journal-title":"Elife"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0295","article-title":"CD20 as a gatekeeper of the resting state of human B cells","volume":"118","author":"Klasener","year":"2021","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0300","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","volume":"5","author":"Klein","year":"2013","journal-title":"MAbs"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079047","article-title":"CD19 and CD20 targeted vectors induce minimal activation of resting B lymphocytes","volume":"8","author":"Kneissl","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0310","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1172\/JCI40231","article-title":"CD20 deficiency in humans results in impaired T cell\u2013independent antibody responses","volume":"120","author":"Kuijpers","year":"2010","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0315","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1126\/science.abb8008","article-title":"Binding mechanisms of therapeutic antibodies to human CD20","volume":"369","author":"Kumar","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0320","first-page":"162","article-title":"The use of rituximab in the management of refractory dermatomyositis","volume":"16","author":"Kuye","year":"2017","journal-title":"Journal of Drugs in Dermatology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0325","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1474-4422(09)70324-2","article-title":"Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: Case series and characterisation of the antigen","volume":"9","author":"Lancaster","year":"2010","journal-title":"Lancet Neurology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0330","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3899\/jrheum.171495","article-title":"Rituximab in the treatment of refractory anti-HMGCR immune-mediated necrotizing myopathy","volume":"46","author":"Landon-Cardinal","year":"2019","journal-title":"The Journal of Rheumatology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0335","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3233\/JND-180300","article-title":"Efficacy of rituximab in refractory generalized anti-AChR myasthenia gravis","volume":"5","author":"Landon-Cardinal","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0340","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028936","article-title":"Multiple sclerosis pathology","volume":"8","author":"Lassmann","year":"2018","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0345","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nrneurol.2014.117","article-title":"Diagnosis and treatment of chronic acquired demyelinating polyneuropathies","volume":"10","author":"Latov","year":"2014","journal-title":"Nature Reviews. Neurology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0350","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/leu.2013.240","article-title":"Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion","volume":"28","author":"Le Garff-Tavernier","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0355","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1212\/WNL.0000000000002635","article-title":"Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort","volume":"86","author":"Lee","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0360","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s13311-020-00921-7","article-title":"Teratoma removal, steroid, IVIG, rituximab and tocilizumab (T-SIRT) in anti-NMDAR encephalitis","volume":"18","author":"Lee","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0365","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1474-4422(20)30392-6","article-title":"New therapies for neuromyelitis optica spectrum disorder","volume":"20","author":"Levy","year":"2021","journal-title":"Lancet Neurology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0370","doi-asserted-by":"crossref","first-page":"42427","DOI":"10.1074\/jbc.M308802200","article-title":"Store-operated cation entry mediated by CD20 in membrane rafts","volume":"278","author":"Li","year":"2003","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0375","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aab4176","article-title":"Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy","volume":"7","author":"Li","year":"2015","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0380","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jocn.2020.11.043","article-title":"Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: A meta-analysis","volume":"85","author":"Li","year":"2021","journal-title":"Journal of Clinical Neuroscience"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0385","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1182\/blood-2011-01-330357","article-title":"Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy","volume":"118","author":"Lim","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0390","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood.V70.5.1316.1316","article-title":"Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development","volume":"70","author":"Loken","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0395","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.coi.2008.03.003","article-title":"Cytokine-producing B lymphocytes-key regulators of immunity","volume":"20","author":"Lund","year":"2008","journal-title":"Current Opinion in Immunology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0400","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nature Reviews. Disease Primers"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0405","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1093\/brain\/awy151","article-title":"The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells","volume":"141","author":"Machado-Santos","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0410","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/jnnp.2009.197632","article-title":"The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome","volume":"82","author":"Maddison","year":"2011","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0415","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1474-4422(14)70256-X","article-title":"Pathological mechanisms in progressive multiple sclerosis","volume":"14","author":"Mahad","year":"2015","journal-title":"Lancet Neurology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0420","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/acn3.444","article-title":"NMDAR encephalitis: Passive transfer from man to mouse by a recombinant antibody","volume":"4","author":"Malviya","year":"2017","journal-title":"Annals of Clinical Translational Neurology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0425","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1158\/0008-5472.CAN-07-6446","article-title":"Purine-rich box-1-mediated reduced expression of CD20 alters rituximab-induced lysis of chronic lymphocytic leukemia B cells","volume":"68","author":"Mankai","year":"2008","journal-title":"Cancer Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108180_bb0430","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1007\/s00415-021-10744-x","article-title":"Anti-CD20 therapies for multiple sclerosis: Current status and future perspectives","volume":"269","author":"Margoni","year":"2022","journal-title":"Journal of Neurology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0435","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.msard.2019.01.044","article-title":"Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies","volume":"30","author":"Mayer","year":"2019","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0440","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015944","article-title":"A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder","volume":"98","author":"Mealy","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0445","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrrheum.2018.48","article-title":"Risk factors and disease mechanisms in myositis","volume":"14","author":"Miller","year":"2018","journal-title":"Nature Reviews Rheumatology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0450","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1191\/1352458503ms965oa","article-title":"Blood-brain barrier disruption in multiple sclerosis","volume":"9","author":"Minagar","year":"2003","journal-title":"Multiple Sclerosis"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0455","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/BOR.0000000000000432","article-title":"Biologics for idiopathic inflammatory myopathies","volume":"29","author":"Moghadam-Kia","year":"2017","journal-title":"Current Opinion in Rheumatology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0460","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0465","doi-asserted-by":"crossref","DOI":"10.1177\/1756286421999631","article-title":"Treatment response to cyclophosphamide, rituximab, and bortezomib in chronic immune-mediated sensorimotor neuropathies: A retrospective cohort study","volume":"14","author":"Motte","year":"2021","journal-title":"Therapeutic Advances in Neurological Disorders"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0470","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/mus.26804","article-title":"Rituximab in refractory chronic inflammatory demyelinating polyneuropathy","volume":"61","author":"Muley","year":"2020","journal-title":"Muscle & Nerve"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0475","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/ane.13291","article-title":"Efficacy and safety of rituximab in autoimmune encephalitis: A meta-analysis","volume":"142","author":"Nepal","year":"2020","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0480","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jamaneurol.2021.3188","article-title":"Use and safety of immunotherapeutic management of N-methyl\u2011d-aspartate receptor antibody encephalitis: A meta-analysis","volume":"78","author":"Nosadini","year":"2021","journal-title":"JAMA Neurology"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108180_bb0485","first-page":"e376","article-title":"NeuroNEXT NN103 BeatMG Study Team. Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: The BeatMG study","volume":"98","author":"Nowak","year":"2021","journal-title":"Neurology."},{"key":"10.1016\/j.pharmthera.2022.108180_bb0490","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0495","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.arcmed.2014.11.013","article-title":"Role of the blood-brain barrier in multiple sclerosis","volume":"45","author":"Ortiz","year":"2014","journal-title":"Archives of Medical Research"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0500","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","article-title":"The regulation and function of CD20: An \u201cenigma\u201d of B-cell biology and targeted therapy","volume":"105","author":"Pavlasova","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0505","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41582-021-00568-8","article-title":"Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials","volume":"17","author":"Pittock","year":"2021","journal-title":"Nature Reviews. Neurology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0510","doi-asserted-by":"crossref","first-page":"18545","DOI":"10.1074\/jbc.M800784200","article-title":"CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins","volume":"283","author":"Polyak","year":"2008","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0515","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s41577-021-00543-w","article-title":"Autoantibodies in neurological disease","volume":"21","author":"Pruss","year":"2021","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0520","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple Sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0525","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1365-2141.2007.06974.x","article-title":"Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA\/CD16","volume":"140","author":"de Romeuf","year":"2008","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0530","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000975","article-title":"Anti-CD20 disrupts meningeal B-cell aggregates in a model of secondary progressive multiple sclerosis","volume":"8","author":"Roodselaar","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0535","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1126\/science.aaz9356","article-title":"Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab","volume":"367","author":"Roug\u00e9","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0540","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a032037","article-title":"B-cell therapies in multiple sclerosis","volume":"9","author":"Sabatino","year":"2019","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0545","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.msard.2017.09.015","article-title":"Diagnosis and management of Neuromyelitis Optica Spectrum disorder (NMOSD) in Iran: A consensus guideline and recommendations","volume":"18","author":"Sahraian","year":"2017","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0550","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy","volume":"87","author":"Salzer","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0555","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/bjh.14534","article-title":"A phase 1\/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab","volume":"177","author":"Sawas","year":"2017","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0560","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.4049\/jimmunol.1600089","article-title":"Features of human CD3+CD20+ T cells","volume":"197","author":"Schuh","year":"2016","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0565","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40263-020-00704-w","article-title":"Anti-CD20 monoclonal antibodies for relapsing and progressive multiple sclerosis","volume":"34","author":"Sellebjerg","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0570","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.621599","article-title":"Neuronal surface antibody-medicated autoimmune encephalitis (limbic encephalitis) in China: A multiple-center, retrospective study","volume":"12","author":"Shan","year":"2021","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0575","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nbt0517-393","article-title":"Genentech's Ocrevus heralds new chapter in MS treatment","volume":"35","author":"Sheridan","year":"2017","journal-title":"Nature Biotechnology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0580","first-page":"5","article-title":"Expression of cell surface markers after human B lymphocyte activation","volume":"78","author":"Stashenko","year":"1981","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0585","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): A multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0590","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1007\/s00415-020-09823-2","article-title":"Distinguish CIDP with autoantibody from that without autoantibody: Pathogenesis, histopathology, and clinical features","volume":"268","author":"Tang","year":"2021","journal-title":"Journal of Neurology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0595","first-page":"7","article-title":"Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes","volume":"168","author":"Tedder","year":"1986","journal-title":"European Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0600","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0167-5699(94)90276-3","article-title":"CD20: A regulator of cell-cycle progression of B lymphocytes","volume":"15","author":"Tedder","year":"1994","journal-title":"Immunology Today"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0605","doi-asserted-by":"crossref","first-page":"10009","DOI":"10.1016\/S0021-9258(19)81618-6","article-title":"Phosphorylation of the B1 (Cd20) molecule by normal and malignant human lymphocytes-B","volume":"263","author":"Tedder","year":"1988","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0610","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas","volume":"104","author":"Teeling","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0615","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0620","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001088","article-title":"Rituximab treatment and long-term outcome of patients with autoimmune encephalitis: Real-world evidence from the GENERATE registry","volume":"8","author":"Thaler","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0625","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.1016\/S0021-9258(18)53411-6","article-title":"Cell type- and stage-specific expression of the CD20\/B1 antigen correlates with the activity of a diverged octamer DNA motif present in its promoter","volume":"268","author":"Th\u00e9venin","year":"1993","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0630","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0635","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/intimm\/dxh009","article-title":"Mouse CD20 expression and function","volume":"16","author":"Uchida","year":"2004","journal-title":"International Immunology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0640","first-page":"5","article-title":"Expression of the human B-cell surface protein CD20_ alteration by phorbol 12-myristate 13-acetate","volume":"84","author":"Valentine","year":"1987","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0645","doi-asserted-by":"crossref","first-page":"16971","DOI":"10.1074\/jbc.M708459200","article-title":"Induction of cytosolic calcium flux by CD20 is dependent upon B cell antigen receptor signaling","volume":"283","author":"Walshe","year":"2008","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0650","doi-asserted-by":"crossref","first-page":"E45","DOI":"10.1002\/mus.26707","article-title":"Refractory myasthenia gravis successfully treated with ofatumumab","volume":"60","author":"Waters","year":"2019","journal-title":"Muscle & Nerve"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0655","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: Mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Seminars in Hematology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102251","article-title":"Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients","volume":"44","author":"Whittam","year":"2020","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0665","doi-asserted-by":"crossref","first-page":"31983","DOI":"10.1074\/jbc.M112.374751","article-title":"Prenyltransferases regulate CD20 protein levels and influence anti-CD20 monoclonal antibody-mediated activation of complement-dependent cytotoxicity","volume":"287","author":"Winiarska","year":"2012","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0670","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3389\/fmed.2020.00303","article-title":"Belimumab and rituximab in systemic lupus erythematosus: A tale of two B cell-targeting agents","volume":"7","author":"Wise","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0675","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1474-4422(20)30342-2","article-title":"Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: A post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial","volume":"19","author":"Wolinsky","year":"2020","journal-title":"Lancet Neurology"},{"key":"10.1016\/j.pharmthera.2022.108180_bb0680","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.736190","article-title":"Effectiveness and safety of rituximab for refractory myasthenia gravis: A systematic review and single-arm Meta-analysis","volume":"12","author":"Zhao","year":"2021","journal-title":"Frontiers in Neurology"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725822000742?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725822000742?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:22:46Z","timestamp":1759011766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725822000742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":136,"alternative-id":["S0163725822000742"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108180","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinct mechanisms underlying therapeutic potentials of CD20 in neurological and neuromuscular disease","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108180","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108180"}}